The Innovative Targets Portfolio: Basic Life Sciences Research to Novel Therapies, through a Portfolio of Small Molecule Translational Projects
Lead Research Organisation:
University of Dundee
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Publications
Heap RE
(2017)
Identifying Inhibitors of Inflammation: A Novel High-Throughput MALDI-TOF Screening Assay for Salt-Inducible Kinases (SIKs).
in SLAS discovery : advancing life sciences R & D
Petit A
(2018)
A structural study of the complex between neuroepithelial cell transforming gene 1 (Net1) and RhoA reveals a potential anticancer drug hot spot
in Journal of Biological Chemistry
| Description | Diamond XChem screen for FabA |
| Amount | £20,000 (GBP) |
| Organisation | Diamond Light Source |
| Sector | Private |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 03/2018 |
| Description | Eastbio PhD studentship |
| Amount | £140,000 (GBP) |
| Organisation | East of Scotland BioScience (EastBio) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 08/2020 |
| Description | drug discovery funding |
| Amount | £14,860 (GBP) |
| Organisation | Tenovus Cancer Care |
| Department | Tenovus Scotland |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| Description | Open innovation (AZ-OGA) |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The University of Dundee will use their OGA assay platform to screen the AZ compound libraries in order to identify new classes of OGA inhibitor. If suitable compounds are identified The University of Dundee will conduct structural biology, Medicinal chemistry and associated drug discovery activities to develop the hit compounds toward in vivo leads. |
| Collaborator Contribution | AZ will provide access to AZ screening facilities and will provide access to proprietary compound libraries. |
| Impact | Project in early stages and no outputs generated to date. |
| Start Year | 2016 |
| Description | Research Collaboration Agreement with AstraZeneca |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Dundee presented a drug target that had been screened in the DDU in 2013. Confirmed hits were optimised but not further developable. We discussed with AZ a desire to screen against a different library to look for new start points |
| Collaborator Contribution | AZ have provided diversity and fragment libraries to Dundee |
| Impact | A new diversity screen will be completed q1 2017 |
| Start Year | 2016 |